The latest from small and Emerging Pharma companies featuring Aligos Therapeutics, Xiamen Amoytop Biotech, Spyre Therapeutics, Beeline Medicines, Allogene Therapeutics, and Terremoto Biosciences. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Aligos Therapeutics, Xiamen Amoytop Biotech in $445-M Hepatitis B Drug Pact 
* Spyre Therapeutics Seeks to Raise $403 M  
* Beeline Medicines Raises $300-M in Company Debut 
* Allogene Therapeutics Seeks to Raise $175 M 
* Terremoto Biosciences Raises $108 M for Oncology Drug Programs 

---

Aligos Therapeutics, Xiamen Amoytop in $445-M Hepatitis B Drug Pact 
Aligos Therapeutics, a clinical-stage bio/pharmaceutical company focused on liver and viral diseases, has entered into an exclusive license agreement to develop and commercialize in Greater China (Mainland China, Taiwan, Hong Kong, and Macau) pevifoscorvir sodium with Xiamen Amoytop Biotech, a Xiamen, China-based bio/pharmaceutical company. Pevifoscorvir sodium is a drug for treating chronic hepatitis B virus infection. 

Under the agreement, Aligos will receive an upfront milestone of $25 million and is eligible to receive up to $420 million in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop’s licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the US, Europe, South Korea, Japan, and all other markets. 

Source: Aligos Therapeutics 

---

Spyre Therapeutics Seeks to Raise $403 M  
Spyre Therapeutics, a clinical-stage bio/pharmaceutical company focused on the treatment of inflammatory bowel disease and other immune-mediated diseases, is seeking to raise $403 million through a follow-on stock offering of 6.5 million shares priced at $62 per share. Spyre’s lead candidate is SPY001, in Phase II for treating ulcerative colitis.  

Source: Spyre Therapeutics 

---

Beeline Medicines Raises $300-M Series A Financing for Company Debut 
Beeline Medicines Corporation, a clinical-stage bio/pharmaceutical company, has announced its official debut by raising $300 million in Series A financing led by Bain Capital. The company has a focus on therapies for autoimmune and inflammatory diseases. Originally formed in July 2025, the company’s initial portfolio is comprised of five programs in-licensed from Bristol Myers Squibb for treating immune-mediated conditions. 

Source: Beeline Medicines 

---

Allogene Therapeutics Seeks to Raise $175 M  
Allogene Therapeutics, a pharmaceutical company focused on allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease, is seeking to raise $175 million through a follow-on stock offering of 87.5 million shares priced at $2 per share. 

Source: Allogene Therapeutics 

---

Terremoto Biosciences Raises $108-M for Oncology Drug Programs 
Terremoto Biosciences, a South San Francisco, California-based bio/pharmaceutical company developing small-molecule medicines, has closed $108 million Series C financing round for its oncology programs. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. 

Terremoto’s lead oncology program, TER-2013, is currently in Phase I clinical development for solid tumors. The company is also advancing TER-4480, a program targeting hereditary hemorrhagic telangiectasia (HHT), a rare, inherited bleeding disorder. TER-4480 is expected to enter the clinic later this year (2026). 

Source: Terremoto Biosciences